Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

Autor: Deibel E; University Hospital Zurich, University of Zurich, Zurich, Switzerland., Carreira PE; 12 de Octubre University Hospital, Madrid, Spain., Vonk M; Radboud University Medical Center, Nijmegen, The Netherlands., Del Papa N; ASST G. Pini-CTO, University of Milan, Milan, Italy., Bečvář R; 1st Medical School, Charles University, Praha, Czech Republic., Guillén-Del-Castillo A; Hospital Universitario Vall d'Hebron, Barcelona, Spain., Campochiaro C; IRCCS San Raffaele Hospital, Milan, Italy., Poormoghim H; Firoozgar Hospital, Tehran, Iran., Liem S; Leiden University Medical Center, Leiden, The Netherlands., Lazzaroni MG; ASST Spedali Civili of Brescia, University of Brescia, Italy., Giollo A; University of Verona, Verona, Italy., Mekinian A; Hôpital Saint Antoine, Paris, France., de Vries-Bouwstra J; Leiden University Medical Center, Leiden, The Netherlands., De Santis M; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy, and Humanitas University, Pieve Emanuele, Milan, Italy., Balbir-Gurman A; B. Shine Rheumatology Institute, and Technion, Haifa, Israel., Mihai C; University Hospital Zurich, University of Zurich, Zurich, Switzerland., De Luca G; IRCCS San Raffaele Hospital, Milan, Italy., Moiseev S; Sechenov First Moscow State Medical University, Moscow, Russian Federation., Zanatta E; University of Padova, Padova, Italy., Foti R; A.O.U. Policlinico S. Marco Catania, Catania, Italy., Rednic S; University of Medicine & Pharmacy 'Iuliu Hatieganu' Cluj, Cluj-Napoca, Romania., Denton C; Royal Free and University College London Medical School, London, UK., Cutolo M; University of Genova, Genova, Italy., Belloli L; ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Airo P; ASST Spedali Civili of Brescia, University of Brescia, Italy., Garzanova L; VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation., Moroncini G; Università Politecnica delle Marche, Polo Didattico, University of Ancona, Ancona, Italy., İnanç M; Istanbul University, Istanbul, Turkey., Panopoulos S; National and Kapodistrian University of Athens Medical School, Athens, Greece., Tandaipan JL; Hospital Universitari de la Santa Creu I Sant Pau, Barcelona, Spain., Chatelus E; Centre National de Référence des Maladies Auto-immunes et Systémiques Rares Est/Sud-Ouest (RESO), Strasbourg, France., Rosato E; Sapienza University of Rome, Rome, Italy., Kuwana M; Nippon Medical School, Tokyo, Japan., Yavuz S; University of Marmara, Istanbul, Turkey., Alegre-Sancho JJ; Hospital Universitario Dr Peset, Comunitat Valenciana, Spain., Smith V; Ghent University, Ghent University Hospital, and VIB Inflammation Research Center (IRC), Ghent, Belgium., Szűcs G; University of Debrecen, Debrecen, Hungary., Henes J; Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany., Rodríguez-Pintó I; Hospital Universitari Mútua de Terrassa, Barcelona, Catalonia, Spain., Atzeni F; University of Messina, Messina, Italy., Spierings J; University Medical Center Utrecht, Utrecht, The Netherlands., Truchetet ME; Université de Bordeaux, Bordeaux, Aquitaine, France., Milchert M; Pomeranian Medical University in Szczecin, Szczecin, Poland., Brito de Araujo D; Universidade Federal de Pelotas, Pelotas, Brazil., Riemekasten G; University Clinic Schleswig Holstein Lübeck, University of Lübeck, Lübeck, Germany., Bernardino V; Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal., Martin T; Centre de Référence des Maladies Autoimmunes Systémiques Rares Est Sud-Ouest (RESO), Nouvel Hôpital Civil, Strasbourg, France., Del Galdo F; Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Biomedical Research Centre, University of Leeds, Leeds, UK., Vacca A; Azienda Ospedaliero Universitaria di Cagliari, Cagliari, Italy., Mendoza F; Thomas Jefferson University, Philadelphia, Pennsylvania., Midtvedt Ø; Oslo University Hospital, Oslo, Norway., Murdaca G; University of Genova and IRCCS Ospedale Policlinico San Martino, Genova, Italy., Santiago T; Centro Hospital e Universitário de Coimbra, University of Coimbra, Portugal., Codullo V; IRCCS Policlinico S. Matteo University Hospital, Pavia, Italy., Cacciapaglia F; University of Bari 'Aldo Moro,', Bari, Italy., Walker U; Universitätsspital Basel, Basel, Switzerland., Brunborg C; Oslo University Hospital, Oslo, Norway., Tirelli F; University Hospital Zurich, University of Zurich, Zurich, Switzerland, and University of Padova, Padova, Italy., Allanore Y; Cochin Hospital, Université de Paris, Paris, France., Furst DE; University of California, Los Angeles., Matucci M; University of Florence, Florence, Italy and IRCCS San Raffaele Hospital, Milan, Italy., Gabrielli A; Università Politecnica delle Marche, Polo Didattico, University of Ancona, Ancona, Italy., Distler O; University Hospital Zurich, University of Zurich, Zurich, Switzerland., Hoffmann-Vold AM; University Hospital Zurich, University of Zurich, Zurich, Switzerland and Oslo University Hospital, Oslo, Norway.
Jazyk: angličtina
Zdroj: Arthritis care & research [Arthritis Care Res (Hoboken)] 2024 Jan; Vol. 76 (1), pp. 88-97. Date of Electronic Publication: 2023 Dec 11.
DOI: 10.1002/acr.25226
Abstrakt: Objective: The outcome of patients with COVID-19 improved over the pandemic, including patients with systemic rheumatic diseases. However, data on patients with systemic sclerosis (SSc) are lacking. This study aimed to assess the outcome of patients with both SSc and COVID-19 over several waves.
Methods: Patients with both SSc and COVID-19 who were registered in the European Scleroderma Trials and Research group (EUSTAR) were collected between April 2020 and April 2021. Patients were assigned to waves 1, 2, or 3 depending on the date of their COVID-19 diagnosis. Primary endpoints were death, intensive care unit stay, or ventilatory support (severe outcome). Subgroup analyses of patients who were hospitalized or died were conducted. General and SSc-specific characteristics and treatment were compared over the waves. Descriptive statistics and multivariate logistic regression were applied.
Results: A total of 333 patients were included; 57 patients (17%) had a severe outcome, and 30 patients (9%) died. Compared to wave 1, significantly fewer patients with SSc suffered from severe COVID-19 in waves 2 and 3 (28.2% vs 9.8% and 12.7%; P < 0.001), fewer patients required hospitalization (46.7% vs 19.6% and 25.5%; P < 0.001) or ventilatory support (24.0% vs 8.7% and 10.9%; P = 0.001), and fewer patients died (15.7% vs 5.0% and 7.5%; P = 0.011). Patients were significantly younger, more often men, had less frequent arterial hypertension, and less SSc cardiac involvement over waves 1 to 3. Patients received significantly less medium to high doses of corticosteroids as they did SSc treatment.
Conclusion: The outcome of patients with both SSc and COVID-19 improved significantly over time because of intrinsic and extrinsic factors.
(© 2023 The Authors. Arthritis Care & Research published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
Databáze: MEDLINE
Externí odkaz: